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Role of the INK4a Locus in Tumor Suppression
and Cell Mortality
Manuel Serrano,*² Han-Woong Lee,*³ Lynda Chin,³ p16INK4a, was first observed as a CDK4-associated pro-
tein in human cells (Xiong et al., 1993) and was subse-Carlos Cordon-Cardo,§ David Beach,²
quently cloned and characterized as a specific inhibitorand Ronald A. DePinho³
of the CDK4±6/D kinases (Serrano et al., 1993; Hannon²Howard Hughes Medical Institute
and Beach, 1994). Three other members of the INK4Cold Spring Harbor Laboratory
family have since been isolated (p15INK4b, p18INK4c, and1 Bungtown Road
p19INK4d). Each shares biochemical and biological prop-Cold Spring Harbor, New York 11724
erties with p16INK4a but is subject to different transcrip-³Department of Microbiology and Immunology
tional regulation (reviewed by Sherr and Roberts, 1995).Albert Einstein College of Medicine
The critical substrate of the CDK4±6/D kinases in vivoBronx, New York 10461
is the retinoblastoma-susceptibility tumor suppressor§Memorial Sloan-Kettering Cancer Center
protein (Rb) (reviewed by Weinberg, 1995). Rb negatively1275 York Avenue
controls passage from G1 into S phase by sequesteringNew York, New York 10021
transcription factors that are required for the G1/S tran-
sition. The ability of Rb to bind transcription factors is
abolished by phosphorylation that occurs in G1 and is
Summary sustained to the end of mitosis. Overexpression of the
CDK4±6 inhibitor p16INK4a results in G1 arrest in cells with
The cell cycle inhibitor p16INK4a is inactivated in many functional Rb, but is without effect in cells with inactive
human tumors and in families with hereditary mela- Rb (Guan et al., 1994; Serrano et al., 1995; Lukas et al.,
noma and pancreatic cancer. Tumor-associated alter- 1995a; Koh et al., 1995; Medema et al., 1995).
ations in the INK4a locus may also affect the overlap- The locus encoding p16INK4a, named INK4a, has the
ping gene encoding p19ARF and the adjacent gene capacity to give rise to two distinct transcripts from
encoding p15INK4b, both negative regulators of cell pro- different promoters (Duro etal., 1995; Stone et al., 1995a;
liferation. We report the phenotype of mice carrying a Mao et al., 1995). Each transcript has a specific 59 exon,
targeted deletion of the INK4a locus that eliminates E1a or E1b, which is spliced into common exons E2 and
both p16INK4a and p19ARF. The mice are viable but de- E3. The E1a-containing transcript encodes p16INK4a, and
velop spontaneous tumors at an early age and are the E1b-containing transcript encodes p19ARF from a
different reading frame initiated in the E1b exon (Quellehighly sensitive to carcinogenic treatments. INK4a-
et al., 1995a). p19ARF has the ability toarrest cell prolifera-deficient primary fibroblasts proliferate rapidly and
tion at both G1 and G2, albeit through mechanisms nothave a high colony-formation efficiency. In contrast
involving direct inhibition of known CDK±cyclin com-with normal cells, the introduction of activated Ha-ras
plexes (Quelle et al., 1995a). Another level of complexityinto INK4a-deficient fibroblasts can result in neoplas-
at the INK4a locus results from its close physical proxim-tic transformation. These findings directly demon-
ity to the gene encoding p15INK4b, an inhibitor thoughtstrate that the INK4a locus functions to suppress neo-
to play an integral role in transforming growth factorplastic growth.
(TGF)b±induced cell-cycle arrest (Hannon and Beach,
1994).
Introduction The involvement of p16INK4a in the development of hu-
man tumors was implied by the observation that the
The cell cycle is controlled by the sequential activation INK4a locus (also called MTS1, CDK4I, or CDKN2) is
and inactivation of protein kinases known as cyclin- mutated in many tumor-derived cell lines and maps to
dependent kinases (CDKs) (reviewed by Hunter and a chromosomal region frequently altered in human ma-
Pines, 1994). Each CDK associates with a cyclin subunit, lignancies (Kamb et al., 1994; Nobori et al., 1994; Oka-
which is essential for catalytic activity and probably sub- moto et al., 1994). A vast amount of data has since
strate recognition. Among the members of the cyclin accumulated implicating the loss of p16INK4a function in
family, D1 was isolated as an oncogene and as a possi- the development of a wide spectrum of tumors. Several
ble effector of mitogen-induced proliferation acting dur- mechanisms of p16INK4a inactivation have been charac-
ing the G1 phase of the cell cycle (Motokura et al., 1991; terized whose prevalence varies with the type of tumor.
Xiong et al., 1991; Matsushime et al., 1991). The predom- Point mutations and small deletions are common in
inant CDK partners activated by cyclin D1 are the closely pancreatic adenocarcinomas, esophageal carcinomas,
related kinases CDK4 and CDK6 (Matsushime et al., biliary tract cancers, and in families with hereditary sus-
1992; Xiong et al., 1992; Meyerson and Harlow, 1994; ceptibility to melanoma and pancreatic cancer (re-
Bates et al., 1994). The activity of these kinases is sub- viewed by Pollock et al., 1996; and by Hirama and Koef-
fler, 1995; see also Yoshida et al., 1995; Hussussian etject to additional levels of regulation, including the asso-
al., 1994; Goldstein et al., 1995; Whelan et al., 1995). Inciation with inhibitory subunits (reviewed by Morgan,
general, the mutations in the INK4a locus that have been1995; Sherr and Roberts, 1995). One such inhibitor,
identified to date affect p16INK4a either exclusively
(z50%) or together with p19ARF (Quelle et al., 1995a). In
the particular case of Dutch and Australian families with*The first two authors contributed equally to this work.
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hereditary melanoma, most of the INK4a-predisposing 1). In normal cells, CDK4 is a component of at least
mutations are located in exon E1a, thus affecting exclu- two different multiprotein complexes: an active complex
sively p16INK4a (Gruis et al., 1995; Walker et al., 1995; consisting of CDK4, cyclin D1, p21, and proliferating cell
Holland et al., 1995). A large proportion of the point nuclear antigen (PCNA), in which PCNA is brought into
mutations found in the INK4a locus are nonsense in the complex through association with the carboxytermi-
the frame encoding p16INK4a (up to 45% in melanomas; nal domain of p21; and an inactive complex consisting
reviewed by Pollock et al., 1996), whereas no nonsense of CDK4 and p16INK4a (Xiong et al., 1993; reviewed by
mutations have been found in p19ARF (Quelle et al., Sherr and Roberts, 1995). These two complexes were
1995a). A second type of p16INK4a inactivation consists present in anti-CDK4 immunoprecipitates from INK4a1/1
of large homozygous deletions that eliminate the INK4a MEFs (Figure 1C, lanes 7 and 8). In contrast, CDK4 was
locus and, in most cases, also involve INK4b (z80%; associated with cyclin D1, p21, and PCNA, but not with
Stone et al., 1995b). Homozygous deletions are common p16INK4a in INK4a2/2 cells (Figure 1C, lanes 9 and 10).
in non-small cell lung carcinomas, malignant gliomas, Although the labeling of p21 is weak, its presence in the
renal cell carcinomas, head and neck tumors, prostate complexes can be inferred by the coimmunoprecipita-
tumors, bladder carcinomas, and acute lymphoblastic tion of PCNA. Anti-CDK6 immunoprecipitates also re-
leukemias (reviewed by Hirama and Koeffler, 1995; see vealed the presence of p16INK4a in INK4a1/1 but not in
also Orlow et al., 1995; Gonzalez-Zulueta et al., 1995a; INK4a2/2 MEF lysates (Figure 1C, compare lanes 2 and
Williamson et al., 1995; Cairns et al., 1995). Finally, meth- 3 with lanes 5 and 6). These results confirm that the
ylation of the INK4a locus is common in breast and colon INK4a2/2 mice do not carry INK4a, and that loss of
cancers and results in silencing of the p16INK4a promoter p16I NK 4 a does not produce discern ible additional
(Herman et al., 1995; Gonzalez-Zulueta et al., 1995b), changes in the composition of CDK4 and CDK6 com-
but not of the p19ARF promoter (Mao et al., 1995; Shapiro plexes in INK4a2/2 fibroblasts.
et al., 1995a).
To explore directly the role of the INK4a locus in both Phenotype of INK4a2/2 Mice
normal development and oncogenesis, we have intro- Homozygous null INK4a2/2 mice are viable and fertile.
duced into the mouse germline an INK4a-null allele that
External examination of the INK4a2/2 mice revealed that
eliminates both p16INK4a and p19ARF.
this genotype cosegregates with a lighter coat pigmen-
tation. However, thegenetic background of the INK4a2/2Results
mice (derived from parental strains C57BL/6 and WW6
that is ≈75% 129/Sv, ≈20% C57BL/6, and ≈5% SJL; Ioffe
Generation of INK4a-Deficient Mice
et al., 1995) is heterogeneous for a number of loci that
A genomic fragment containing mouse INK4a exons E2
affect coat color (Silvers, 1979). This complexity pre-
and E3 (Quelle et al.,1995b) servedas a source of homol-
sently precludes a precise assessment of the possibleogous sequences for the construction of a positive/neg-
impact of INK4a deficiency on melanocyte function untilative replacement-type vector, p16KO, in which exons
fully inbred strains are generated. On inspection,E2 and E3 were replaced with a neor cassette (Figure 1A).
INK4a2/2 organs aged 2 months or younger were normalp16KO was electroporated into WW6 mouse embryonic
in size and appearance. However, histological analysisstem (ES) cells (Ioffe et al., 1995), and one clone was
of the spleen revealed a mild proliferative expansion ofidentified that contained restriction fragment±length al-
the white pulp and the presence of numerous megakary-terations consistent with disruption of the INK4a locus
ocytes and lymphoblasts in the red pulp (data not(see also Figure 1B, lanes 1±3). This ES clone was used
shown). These features are consistent with abnormalto generate germline chimeras following microinjection
extramedullary hematopoietic processes in the spleeninto C57BL/6 blastocysts. Upon mating with C57BL/6
of young INK4a2/2 mice. In adult INK4a2/2 mice (>6mice, these chimeras produced WW6/B6 F1 offspring
months), extramedullary hematopoiesis becomes moreharboring the mutant INK4a al lele. An addi tional
severe in the spleen and is present in nonlymphoid or-INK4a1/2 ES clone was obtained by electroporation of
gans such as the liver (data not shown). We have consis-E14 ES cells, but the chimeras obtained did not transmit
tently found normal hematocrit levels in the INK4a2/2the INK4a-null allele to their offspring.
mice, thus excluding anemia as an indirect promotingGenotype analysis of live offspring from INK4a1/2 in-
factor underlying extramedullary hematopoiesis. To-tercrosses revealed that all three genotypes were repre-
gether, these findings suggest that INK4a could nega-sented with a ratio close to the expected Mendelian
tively regulate the proliferation of some hematopoieticdistribution (relative ratios 1 (1/1), 1.7 (1/2), 1 (2/2),
lineages or their progenitors.n 5 521). Disruption of the INK4a locus was further
verified on three levels. First, Southern blot analysis us-
Tumor Susceptibility of INK4a2/2 Miceing a cDNA probe containing exons E2 and E3 demon-
To assess the role of the INK4a locus in tumor suppres-strated that these exons were eliminated from the ge-
sion, we randomly assigned litters arising from heterozy-nome of INK4a2/2 offspring (Figure 1B, lane 6). Second,
gous intercrosses to either untreated or carcinogen-a similar cDNA probe failed to detect p16INK4a or p19ARF
treated groups and then measured the rate of tumortranscripts in total RNA derived from INK4a2/2 mouse
formation. In total, over 500 mice ranging in age fromembryonic fibroblasts (MEFs) but not from INK4a1/1 or
1±10 months (>100 older than 6 months) and represent-INK4a1/- MEFs (data not shown). Third, immunoprecipi-
ing all three genotypes were monitored daily for thetation of [35S]methionine±labeled MEF lysates with anti-
development of overt tumors or ill health. Among un-p16INK4a confirmed the absence of p16INK4a from homozy-
gous null embryos (Figure 1C, compare lane 4 with lane treated INK4a2/2 mice, 69% (from a total population size
INK4a Knockout Mouse
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Figure 1. Disruption of the INK4a Locus in
Mouse ES Cells and Generation of INK4a-
Deficient Mice
(A) Targeting strategy. The murine p16INK4a
coding exons, E1a, E2 and E3, are indicated
with closed boxes (Quelle et al., 1995b). The
p19ARF-specific exon E1b is indicated with an
open box (Quelle et al., 1995a) and has been
placed upstream of exon E1a based on the
location of human E1b (Duro et al., 1995;
Stone et al., 1995a; Mao et al., 1995). Abbrevi-
ations for restriction endonucleases: P, PstI;
S, SalI; Sc, SacI; N, NotI; Nh, NheI; B, BamHI;
X, XbaI. The precise positions of two PstI
sites in the 59-region (2P) and one PstI site in
the 39-region (P) have not been determined.
Homologous recombination replaces exons
E2 and E3 with the pgk±neo cassette and
introduces PstI and XbaI sites.
(B) Southern blot of PstI-digested tail DNA
from the offspring of INK4a1/2 intercrosses.
Probe A is a 1.3 kb BamHI fragment; probe
B is a 0.4 kb PCR-generated probe corre-
sponding to exons E2 and E3. Southern anal-
ysis of XbaI±digested genomic DNAs was
consistent with the results obtained with
PstI±digested DNAs (data not shown). PCR
and Southern analysis indicated that the ad-
jacent INK4b gene is present in INK4a-defi-
cient mice. Similarly, the junction between the
59 homologous region and the outside flank-
ing sequence (around the SalI site) is also
conserved in the INK4a-deficient mice.
(C) Immunoprecipitation of p16INK4a, CDK4,
and CDK6 complexes from MEFs. Cellular ly-
sates were incubated with antibodies against
p16INK4a, CDK4, or CDK6, in the absence or
presence of appropriate competing peptides,
as indicated.
of n 5 13) developed histologically confirmed tumors at for its carcinogenic effects in mice (reviewed by Kripke,
1994). In the selection of these protocols, we took intoan average age of 29 weeks during an observation pe-
riod of 36 weeks (Figure 2A; Table 1). In contrast, none account the fact that C57BL/6 mice are poorly suscepti-
ble to the development of papillomas and squamousof their INK4a1/1 or INK4a1/2 littermates developed any
obvious tumors or displayed compromised health after cell carcinomas in the skin induced by standard two-
stage carcinogenic treatments with DMBA initiation and36 weeks.
The susceptibility of each genotype to tumor induction phorbol ester promotion (reviewed by DiGiovanni, 1991).
In the DMBA/UVB±treated cohort, only 10% of INK4a2/2by carcinogenswas assessedusing three different treat-
ments: a two-stage protocol consisting of a single appli- mice remained free of obvious tumors or compromised
health during an observation period of 20 weeks (Figurecation of 9,10-dimethyl-1,2-benzanthracene (DMBA) fol-
lowed by repeated irradiation with ultraviolet B (UVB) 2B). Specifically, twenty INK4a2/2 mice were followed:
twelve mice developed clinically apparent and histologi-(280±320 nm); treatment with DMBA alone; and expo-
sure to UVB alone. DMBA is a well-characterized muta- cally confirmed malignancy (see Table 1); three mice
died suddenly for unknown reasons and a comprehen-gen and carcinogen that forms covalent DNA adducts
(reviewed by DiGiovanni, 1991). The relationship be- sive histological survey failed to identify tumor forma-
tion; finally, three mice died without clinically apparenttween UVB exposure and carcinogenic response is well
documented (de Gruijl and van der Leun, 1991); in addi- tumors but advanced autolysis precluded an informative
histological analysis. The average latency of tumor for-tion to its action as a mutagen, UVB induces a marked
systemic immunosuppression that is partly responsible mation in the group of twelve mice with histologically
Cell
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marker protein (Figure 3B), keratins, or desmin (data not
shown); these results indicate that these tumors are
not melanomas, carcinomas, or myogenic sarcomas,
respectively. However, cells were positive for vimentin,
thus favoring the diagnosis of fibrosarcoma (Figure 3C).
Another type of vimentin-positive sarcoma showed
characteristic features of a highly vascularized angiosar-
coma with neoplastic cells in the lumina of ill-defined
vessels (data not shown). The second major histological
tumor category exhibited a more generalized distribu-
tion and primarily involved lymphoid organs. The normal
architecture of the affected lymph nodes was com-
pletely effaced by small round cells with hyperchromatic
nuclei, prominent nucleoli, scanty cytoplasm, and nu-
merous and bizarre mitotic figures. These tumor cells
displayed positive surface immunostaining with anti-
CD45 and B220 antibodies, but were unreactive with
anti-CD3, establishing the diagnosis of B cell lymphoma
(Figures 3D, 3E, and 3F; data not shown). The spectra
of tumor types arising in untreated animals and in carcin-
ogen-treated animals were similar, although three
Figure 2. Survival Curves of INK4a-Deficient Mice in the Absence INK4a2/2 mice and one INK4a1/2 mouse in the carcino-
or Presence of Carcinogenic Treatments gen-treated groups developed cutaneous lesions that
(A) Untreated and UVB-treated mice. proved to be well-differentiated squamous cell carcino-
(B) DMBA/UVB-treated mice.
mas (see Table 1). In summary, mice lacking INK4a are(C) DMBA-treated mice. In the INK4a2/2 group, three mice devel-
particularly susceptible to the development of sarcomasoped clinically apparent tumors, andtwo mice died without clinically
and lymphomas.apparent tumors but could not be subjected to autopsy due to
autolysis. In the INK4a1/2 group, one mouse developed a tumor,
and one mouse died but could not be subjected to autopsy due to Growth Properties of INK4a2/2 MEFs
autolysis. Two observations point to a role for INK4a as a regulator
of normal fibroblast growth. First, INK4a-deficient mice
confirmed malignancies was 9 weeks. In comparison, develop fibrosarcomas with high frequency (see Table
83% of the twenty-three INK4a1/2 mice and 100% of 1) and, second, p16INK4a appears to be the major INK4
the twenty-seven INK4a1/1 littermates remained healthy protein associated with CDK4 and CDK6 in normal
and tumor-free, although occasional histologically be- mouse embryonic fibroblasts (see Figure 1C). Accord-
nign papillomas were observed. Four INK4a1/2 mice de- ingly, we have studied the growth properties of primary
veloped slow-growing histologically verified tumors with MEFs derived from individual embryos. Cultures of
an average latency of 15 weeks (see Table 1). In the INK4a2/2 MEFs were morphologically indistinguishable
group of animals treated with DMBA alone, the percent- from INK4a1/1 MEFs. Early-passage INK4a2/2 MEFs grew
age of survival was higher and the latency of tumor significantly faster than early-passage INK4a1/1 or
development was longer than that of the DMBA/UVB INK4a1/2 MEFs, and the INK4a2/2 MEFs monolayers
group (e.g., latency was 13 weeks for INK4a2/2 mice;
achieved higher cellular densities (Figure 4A). Compared
Figure 2C, legend). The group of INK4a2/2 mice treated
with INK4a1/1 MEFs, analysis of the different cell cycle
with UVB alone developed tumors with kinetics that were
stages during exponential growth revealed a moderate
indistinguishable from those of the untreated mice (64%
increase in the S phase population of the INK4a2/2 MEFs,
of mice developed tumorsat an average age of 28weeks
accompanied by a concomitant decrease in the G0/G1during an observation period of 36 weeks, n511; see
population (Figure 4B). A quantitatively similar changeFigure 2A). This suggests that UVB potentiates the carci-
on cell-cycle distribution has been reported for Rb2/2nogenicity of DMBA but, when used alone under the
MEFs (Lukas et al., 1995b).conditions employed, is not tumorigenic (compare Fig-
The ability of primary cell cultures to produce coloniesures 2A, 2B, and 2C). None of the UVB-treated INK4a1/1
of clonal origin is related to the proliferative potential ofor INK4a1/2 mice have developed tumors (data not
the cells (Kraemer et al., 1986; Conzen and Cole, 1995).shown). Together, these findings demonstrate that the
INK4a2/2 early-passage MEFs formed colonies more effi-absence of INK4a results in increased susceptibility to
ciently than INK4a1/1 MEFs (Figure 4C), suggesting thatthe development of cancers.
INK4a2/2 cells can overcome senescence more easilyAt the histopathological level, the spectrum of tumors
than their wild-type counterparts. Normal primary MEFsin the INK4a2/2 mice is dominated by two tumor types
initially grow at a constant rate until they enter into a(see Table 1). One, arising in the subcutis and invading
slow-growth phase, or senescence, when they reachthe underlying musculature, is composed of anaplastic
a population doubling level (PDL) of approximately 10spindle cells with frequent mitotic figures (Figure 3A).
doublings (RoÈ hme, 1981; Conzen and Cole, 1995). Spon-Since these features are consistent with either mela-
taneous escape from senescence occurs in normal ro-noma, leiomyosarcoma, or fibrosarcoma, we further
dent cells at a measurable frequency (frequency per celldefined the histogenesis with a battery of immunohisto-
z2 3 106) (Kraemer et al., 1986). Serial passage of twochemical markers. Tumor cells did not show immunore-
activity to antibodiesagainst protein S100, a melanocyte independent INK4a-/- MEFcultures resulted in a constant
INK4a Knockout Mouse
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Table 1. Spontaneous and Induced Tumors in INK4a-Deficient Mice
Agea
Mouse Genotype Sex (weeks) Treatmentb Histologyc Sited
1 2/2 F 20 None Fibrosarcoma Subcutis
2 2/2 F 24 None Fibrosarcoma Subcutis
3 2/2 F 28 None Sarcoma Liver, spleen
4 2/2 F 28 None Liposarcoma, lymphomae Retroperitoneum, generalized
5 2/2 M 30 None Angiosarcoma Subcutis
6 2/2 M 32 None B-cell lymphoma Generalized
7 2/2 F 32 None Lymphoma Generalized
8 2/2 F 32 None Fibrosarcoma Subcutis
9 2/2 F 36 None Lymphomae Generalized
10 2/2 F 18 UV SCC Cutis
11 2/2 F 20 UV Fibrosarcoma Subcutis
12 2/2 F 28 UV Lymphoma Intestine, abdomen
13 2/2 M 28 UV Fibrosarcoma, SCC Subcutis, cutis
14 2/2 M 32 UV Sarcoma Retroperitoneum, abdomen
15 2/2 M 32 UV Fibrosarcoma, lymphoma Subcutis, abdomen
16 2/2 M 32 UV Lymphoma Generalized
17 2/2 F 32 UV Fibrosarcoma Retroperitoneum
18 2/2 M 6 DMBA1UV Fibrosarcoma Subcutis 3 2
19 2/2 F 6 DMBA1UV Fibrosarcoma Subcutis
20 2/2 M 8 DMBA1UV B-cell lymphoma Generalized
21 2/2 F 8 DMBA1UV B-cell lymphoma Generalized
22 2/2 F 8 DMBA1UV Fibrosarcoma Subcutis 3 2
23 2/2 M 10 DMBA1UV Fibrosarcoma Subcutis 3 3
24 2/2 F 10 DMBA1UV Fibrosarcoma, SCC Subcutis, cutis
25 2/2 M 10 DMBA1UV Fibrosarcoma Subcutis 3 2
26 2/2 M 10 DMBA1UV Lymphoma Generalized
27 2/2 F 10 DMBA1UV Lymphoma Generalized
28 2/2 F 10 DMBA1UV Fibrosarcoma Subcutis
29 2/2 F 12 DMBA1UV Fibrosarcoma Subcutis 3 2
30 1/2 F 7 DMBA1UV Lymphoma Subcutis
31 1/2 F 10 DMBA1UV Low grade fibrosarcoma Subcutis
32 1/2 M 18 DMBA1UV SCC Cutis
33 1/2 F 20 DMBA1UV Low grade fibrosarcoma Subcutis
34 Chimera M 4 None Teratoma Subcutis
a Age at the time of tumor detection or death.
b See Experimental Procedures.
c See Experimental Procedures and Figure 3; SCC: squamous cell carcinoma.
d Numbers indicate the presence of more than one tumor of the same type.
e These two mice also had significantly elevated peripheral white blood cell counts and lymphoid or myeloid blast-like cells on peripheral
blood smears, which were suggestive of an associated leukemic state.
and rapid growth rate with no detectable senescent at two different levels (Land et al., 1983; reviewed by
phase and reaching PDLs equal to 56 and 57, respec- Hunter, 1991). Compared with rat cells, neoplastic trans-
tively, after 25 passages. A total of five independent formation of primary MEFs occurs inefficiently and has
INK4a1/1 and INK4a1/2 MEF cultures reached PDLs been observed only with particular pairs of cooperating
ranging from 17±33 after 25 passages and showed a oncogenes (e.g., Ha-rasval12/E1a and Ha-rasval12/CDC25A;
transitory slow-growth phase of variable duration at Lowe et al., 1994; Galaktionov et al., 1995).
PDLs equal to around 12 (data not shown). Although As anticipated, transfection of Ha-rasval12 or myc into
senescence of the INK4a2/2 cells was not detectable at early-passage INK4a1/1 or INK4a1/2 MEFs failed to pro-
the population level, individual cells could be identified duce transformed foci (Table 2). Interestingly, focus for-
showing morphological signs of senescence such as mation was observed in the INK4a2/2 monolayers after
prominent cytoplasmic enlargement. These observa- transfection with Ha-rasval12 but not after transfection
tions, together with the higher colony-formation effi- with myc (Table 2; Figure 5A). In support of these results,
ciency of the INK4a2/2 cells, suggest that loss of INK4a transfection of activated raf (raf-bxb; Bruder et al., 1992)
facilitates spontaneous escape from cellular senes- into INK4a2/2 MEFs produced foci with an efficiency
cence. comparable to that of Ha-rasval12, whereas transfection
of INK4a1/1 MEFs with raf-bxb did not generate foci (M.
White, personal communication). The tumorigenicity ofSusceptibility of INK4a2/2 MEFs
the Ha-rasval12-induced INK4a2/2 fociwas furtherdemon-to Neoplastic Transformation
strated by their ability to grow under anchorage-inde-Neoplastic transformation of primary rodent cells re-
pendent conditions (Figure 5B) and to produce tumorsquires the cooperation of pairs of oncogenes, reflecting
the necessity to disregulate cell proliferation minimally in nude mice (data not shown). These results indicate
Cell
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Figure 3. Histological Analysis of the Spontaneous Tumors Developed by INK4a2/2 Mice
(A±C) Photomicrographs of sections of a subcutaneous tumor processed as follows: (A) Hematoxylin and eosin staining. (B) Immunohistochemi-
cal staining against the melanocyte-marker protein S 100; positive staining corresponds to the section of a peripheral nerve. (C) Immunohisto-
chemical staining against vimentin; the tumor and some invaded muscle fibers are stained.
(D±F) Photomicrographs of sectionsof a lymphnode processed as follows: (D) Hematoxylin andeosin staining. (E) Positive immunohistochemical
surface staining against the leukocyte surface-marker CD45. (F) Positive immunohistochemical surface staining against the B cell surface-
marker B220. Original magnification, 4003.
that INK4a deficiency can cooperate with activated Ha- Discussion
ras to induce the malignant transformation of primary
fibroblasts, and further suggest that loss of INK4a may The hypothesis that p16INK4a is a tumor suppressor is
based on three existing lines of evidence: p16INK4a ne-represent an immortalization event in the transformation
of primary fibroblasts. gates the activity of a known oncogene, cyclin D1, and
Figure 4. Growth Properties of INK4a2/2
Early-Passage MEFs
(A) Growth curves of early-passage MEFs de-
rived from individual embryos wt-8 (INK4a1/1),
sko-12 (INK4a1/2) and dko-6 (INK4a2/2). The
number of cells per 6 cm diameter dish is
indicated. Similar results were obtained with
cultures wt-5, wt-7, sko-1, and dko-9 (wt,
INK4a1/1; sko, INK4a1/-; dko, INK4a2/2).
(B) Analysis of cell cycle stages in exponen-
t ial ly growing cul tures of IN K4a1 / 1 and
INK4a2/2 MEFs derived from individual em-
bryos. Cultures were labeled with anti-BrdU
to detect DNA synthesis (vertical axis) and
propidium iodide to detect total DNA (hori-
zontal axis), and were analyzed by two-di-
mensional fluorescence-activated cell sort-
ing (FACS). INK4a1/1 MEF cultures (wt-4 and
wt-8) and INK4a2/2 MEF cultures (dko-6 and
dko-10) were analyzed. FACS profiles for wt-
8 and dko-10 are shown as an example.
(C) Colony-formation efficiency of INK4a1/1




has the capacity to arrest cell proliferation at G1 in anTable 2. Neoplastic Transformation of INK4a1/1, INK4a1/2,
Rb-dependent manner; p16INK4a is frequently inactivatedINK4a2/2 MEFs
in a variety of human cancers; and inherited INK4a mu-Number of focid
tant alleles that inactivate p16INK4a predispose individuals
Transfected INK4a genotype to the development of malignant melanoma and pancre-
Assaya DNAb 1/1 1/2 2/2 atic adenocarcinoma (see Introduction). Through the
1 Carrier plasmid 0 0 0 generation of INK4a2/2 mice by gene targeting, we pro-
V-myc 0 0 0 vide direct evidence that INK4a deficiency facilitates
Ha-rasval12 0 0 27 tumor development in a mammalian organism. The null
2 Carrier plasmid 0 NDe 0
INK4a allele that has been introduced into the mouseHa-rasval12 0 ND 26
germline also eliminates the recently identified geneHa-rasval12 0 ND 32
p19ARF, which shares two exons with p16INK4a but is trans-Ha-rasval12 c 0 ND 7
3 Carrier plasmid 0 0 0 lated in a different reading frame (Quelle et al., 1995a).
Ha-rasval12 0 0 8 Loss of INK4a does not result in gross congenital
4 Carrier plasmid 0 0 0 defects, indicating that INK4a is not essential for viability
Ha-rasval12 0 0 25 or organomorphogenesis. In accord with our findings,
a The following early-passage MEF cultures, derived from individual two cases of an INK4anull/INK4anull genotype have been
embryos, were used in each assay. Assay 1: wt-7, sko-1, dko-6. reported in humans without attendant developmental
Assay 2: wt-4, dko-6. Assay 3: wt-3, sko-1, dko-6. Assay 4: wt-8, effects (in both cases the INK4a mutation is in exon
sko-12, dko-10. Abbreviations: wt, INK4a1/1; sko, INK4a1/2; dko, E1a) (Gruis et al., 1995). INK4a2/2 mice display features
INK4a2/2.
consistent with abnormal extramedullary hematopoie-b The following plasmids were used: pNV-Ha-rasV12 (Galaktionov
sis, suggesting that INK4a might normally regulate theet al., 1995) encoding human c-Ha-Ras(G12V) under the murine
proliferation of some hematopoietic lineages or theirleukemia virus long terminal repeat (LTR); pSV-v-myc (Land et al.,
1995) encoding avian MC29 virus Myc under its own LTR; an unre- progenitors. A role for INK4a in hematopoiesis is not
lated yeast plasmid, vector pGAD-GL, was used as carrier DNA. unexpected, considering that p16INK4a acts in concert
c In this particular case, c-Ha-Ras(G12V) was encoded by plasmid with Rb and that Rb2/2 mice are severely impaired in the
pDCR-rasV12 (Serrano et al., 1995). production of mature erythrocytes and have increasedd Foci generated after transfection of an initial population of 106
numbers of megakaryocytes and myeloid cells in livercells.
(Lee et al., 1992; Jacks et al., 1992; Clarke et al., 1992).e ND: not done.
INK4a2/2 mice develop spontaneous tumors at an
early age (z69% of the mice before reaching 36 weeks
Figure 5. Neoplastic Transformation of
INK4a2/2 Early-Passage MEFs with Ha-rasval12
(A) Foci-formation assay. Plates correspond
to assay number 1 of Table 2.
(B) Colony-formation assay in soft agar.
Left, wt-8 (INK4a1/1) MEFs; middle, dko-6
(INK4a2/2) MEFs; right, cells from a focus pro-
duced by introduction of Ha-rasval12 into dko-
6 (INK4a2/2) MEFs. Cells from 2 out of 3 ran-
domly chosen dko-6/Ha-rasval12 foci were able
to produce colonies in soft agar.
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of age, and with an average age of 29 weeks) and, com- single regulatory pathway. This pathway can be altered
by inactivation of p16INK4a or Rb, or by amplification ofpared with their INK4a1/1 and INK4a1/2 littermates, are
highly susceptible to the development of tumors follow- the genes encoding CDK4 or cyclin D1. A particular
missense mutation in CDK4 that specifically disruptsing carcinogenic treatments (DMBA/UVB, and DMBA
alone). Although the number of tumors analyzed is lim- thep16INK4a binding sitehas been found insporadic mela-
nomas and also in families with hereditary susceptibilityited, it is clear that INK4a2/2 mice are particularly sus-
ceptible to development of soft-tissue sarcomas and to melanoma who do not carry mutant INK4a alleles
(WoÈ lfel et al., 1995; Zuo et al., 1996). Moreover, thereB cell lymphomas. Inactivation of the INK4a gene is
common in human lymphomas and sarcomas (reviewed are some tumor types in which alteration of one compo-
nent of the p16INK4a/CDK4/D1/Rb pathway occurs in ex-by Hirama and Koeffler, 1995). In addition, the histologi-
cally aggressive nature of the fibrosarcomas arising in clusivity with respect to the alteration of the other com-
ponents (Jiang et al., 1993; Okamoto et al., 1994;INK4a2/2 mice, as judged by overall architecture, degree
of cellular atypia, and mitotic indices, contrasts sharply Schmidt et al., 1994; Maelandsmo et al., 1995; Shapiro
et al., 1995b; He et al., 1995; Ueki et al., 1996). Thiswith the relatively nonaggressive histological picture
seen in the low-grade fibrosarcomas arising in INK4a1/2 pattern of genetic alterations suggests that the p16INK4a/
CDK4/D1/Rb pathway behaves as a single genetic tar-mice. These findings are consistent with the view that
INK4a deficiency may accelerate progression to more get in oncogenic transformation that is altered in the
majority of tumors.malignant tumors. Since Rb1/2 mice develop pituitary
gland tumors (Jacks et al., 1992), we have paid particular
Experimental Proceduresattention to the development of this type of tumor in the
INK4a2/2 mice, and we have failed to detect any sign
Gene Targetingof malignancy. The absence of skin melanomas among
Murine INK4a genomic clones were isolated by screening a 129/Sv
the INK4a2/2 mice might be explained by a need for a mouse D3 genomic l library with the human p16INK4a cDNA. The
longer latency period but, in general, mice are relatively targeting construct, p16KO, was derived from the pPNT vector (Ty-
resistant to the development of cutaneous melanoma bulewicz et al., 1991). p16KO was electroporated into WW6 ES cells
(Ioffe et al., 1995), and clones were selected with G418 (150 mg/ml(DiGiovanni, 1991; Bradl et al., 1991).
active component) and 2 mM ganciclovir. INK4a1/2 ES clones wereAt the cellular level, INK4a deficiency resulted in al-
identified by Southern blot analysis as described in Figure 1, andtered cell growth properties. INK4a2/2 MEFs proliferate
subsequently microinjected into C57BL/6 blastocysts. Resultant
rapidly and show a high colony-formation efficiency. male chimeras with greater than 50% ES contribution, as judged
This cellular phenotype may explain the consistent by coat color, weremated with C57BL/6 females. Germline transmis-
observation that INK4a gene inactivation is more com- sion to agouti offspring was confirmed by Southern blot and PCR
analysis of tail DNA (see Figure 1, legend).mon in tumor cell lines than in the corresponding pri-
mary tumors and is presumably genetically selected for
Immunoprecipitationsgrowth in culture (reviewed by Hirama and Koeffler,
Immunoprecipitations from [35S]methionine±labeled lysates were
1995). In support of a role for the INK4a locus in estab- performed as described (Xiong et al., 1993). The antiserum against
lishing cellular mortality, p16INK4a expression has been murine p16 (Quelle et al., 1995b) was a gift from Drs. D. Quelle and
shown to be up-regulated during senescence (Hara et C. Sherr (St. Jude Children's Research Hospital); antibodies against
murine CDK4 (C-22) were obtained from Santa Cruz Biotechnology,al., 1996). Introduction of activated Ha-ras into primary
Inc.; and the antiserum against CDK6 was a gift from Dr. G. HannonINK4a2/2 fibroblasts can induce neoplastic transforma-
(Cold Spring Harbor Laboratory).tion, a property that is characteristic of immortal rodent
cell lines (Land et al., 1983; Newbold and Overell, 1983; UVB and DMBA Tumorigenic Treatments
Palmieri, 1989; Ruley, 1990; Hunter, 1991). These find- DMBA treatments consisted of a single application of 50 ml of a
ings provide a potential basis for the high incidence of solution 0.5% DMBA (Sigma) in acetone to the dorsal surface on
postnatal day 1±5. The UVB irradiation source was two FS-2OT12/fibrosarcomas in INK4a-deficient mice.
UVB bulbs (National Biological Corp.) with emission peaks at 295The results presented in this paper directly demon-
nm, 305 nm and 310 nm. Irradiance of UVB bulbs was measuredstrate that INK4a is a tumor-suppressor locus. The
prior to each treatment with a photometer calibrated to 310 nm.INK4a locus encodes two overlapping proteins, p16INK4a
UVB treatments consisted of three exposures per week beginning
and p19ARF, and it is adjacent to the INK4b locus, which on postnatal day 4±8. Animals were initially exposed to a UVB dose
encodes the cell-cycle inhibitor p15INK4b. The biological of 100 mJ/cm2 per session (a dose that was determinedto be equiva-
lent to the minimal erythema dose for newborn mice). Dosage wasproperties of p16INK4a and the analysis of the tumor-spe-
increased by 10% per treatment unless erythema or scaling wascific alterations present in the INK4a locus strongly sug-
noted. On average, animals were exposed to z27 UVB sessions,gest that inactivation of p16INK4a is the critical target of the
with a maximum UVB dose set at 700 mJ/cm2. The dorsal surfaceINK4a alterations found in both sporadic and hereditary
of all animals was shaved weekly.
tumors (see Introduction). Based on this presumption,
we propose that the absence of p16INK4a contributes sig- Immunohistochemistry
nificantly to the tumor-susceptibility phenotype of the Normal and tumor tissue samples were either fixed in 10% buffered
formalin and embedded in paraffin, or embedded in OCT compoundINK4a-deficient mice.
(Miles Laboratories) and frozen in liquid nitrogen at 2708C. Sectionsp16INK4a and cyclin D1 are negative and positive regula-
(5 mm) were stained with hematoxylin and eosin, and representativetors, respectively, of CDK4, which, in turn, is responsible
samples were selected for immunohistochemical analysis. Immuno-
for the phosphorylation and inactivation of Rb (see Intro- phenotyping was performed using an avidin±biotin immunoperoxi-
duction). Therefore, two negative regulators of cell pro- dase technique (Cordon-Cardo and Richon, 1994). Primary antibod-
liferation, p16INK4a and Rb, and two inducers of prolifera- ies used included anti-protein S100 (purified rabbit serum, 1:4000
dilution; Dako Corporation), anti-vimentin (goat serum, 1:4000;tion, CDK4 and cyclin D1, are functionally related in a
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Sigma), anti-desmin (goat serum, 1:1000; Sigma), anti-CD45 (rat Award and the Irma T. Hirschl Career Scientist Award, and is sup-
ported by National Institutes of Health grants EY09300 andmonoclonal, 1:10; Pharmingen), anti-CD3 (purified rabbit serum,
1:5000; Dako), and anti-B220 (rat monoclonal, 1:1000; Boehringer HD28317. Work at the Albert Einstein College of Medicine was also
supported by Cancer Center Core National Institutes of Health grantMannheim). Primary antibodies were incubated overnight at 48C.
Samples were subsequently incubated with biotinylated secondary 2P30CA13330.
antibodies (Vector Laboratories) for 30 min (goat anti-rabbit, 1:1000;
rabbit anti-goat, 1:1000; rabbit anti-rat, 1:100), and then with avidin± Received January 23, 1996; revised February 12, 1996.
biotin peroxidase complexes (1:25 dilution; Vector Laboratories) for
30 min. Diaminobenzadine was used as the chromogen and hema- References
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